On March 11, 2026, LeMaitre Vascular (NASDAQ: LMAT) Senior Vice President of Operations Trent G Kamke reported the exercise and immediate sale of 2,625 shares of common stock for total proceeds of approximately $285,000, according to this SEC Form 4 filing.
|
Metric |
Worth |
Context |
|---|---|---|
|
Shares sold (direct) |
2,625 |
Open market shares sold (code ‘S’) in this presentation |
|
Transaction value |
$284,812.50 |
Based on SEC Form 4 weighted average purchase price ($108.50) |
|
Post-transaction actions (direct) |
6,677 |
Directly owned shares after completion of transaction |
|
Post-transaction value (direct ownership) |
~$722,000 |
Based on market close March 11, 2026 |
Transaction value based on SEC Form 4 weighted average purchase price ($108.50); Post-transaction value based on market close on March 11, 2026.
-
What was the structure and rationale of the transaction?
The transaction reflects an exercise of 2,625 vested options immediately followed by an outright sale of common stock, a common mechanism for executives to monetize stock awards while maintaining compliance with the company’s business policies. -
How did this transaction affect Kamke’s shareholding?
Direct common stock holdings decreased from approximately 9,000 shares to 6,677 shares, representing a 28.22% reduction in direct equity exposure; There were no indirect interests involved nor remain after the transaction. -
How does commerce fit into Kamke’s recent activity?
This transaction matches the average sale size of the recent period (2,625 shares) and the percentage of holdings sold per trade (28.22%), indicating consistency in the liquidation cadence, as available direct holdings have decreased over time. -
What ongoing equity exposure does Kamke retain?
Kamke continues to have 1,353 directly held stock options, which may be exercised for additional common shares in the future, preserving potential bullish alignment with the company’s performance.
|
Metric |
Worth |
|---|---|
|
Revenue (TTM) |
$249.6 million |
|
Net income (TTM) |
57.7 million dollars |
|
Dividend yield |
0.99% |
|
1 year price change |
32.90% |
*1 year price change calculated using March 11, 2026 as the reference date.
-
It offers a portfolio of medical devices and implants for the treatment of peripheral vascular diseases, including angioscopes, embolectomy and thrombectomy catheters, carotid bypasses, vascular grafts and closure systems.
-
It generates revenue primarily through direct sales and distributor relationships, focusing on proprietary vascular products designed for surgical interventions and vascular repairs.
-
It serves hospitals, surgeons and healthcare providers treating vascular diseases, with a global customer base spanning North America, Europe and other international markets.